6Pharmacotherapy — Why No Cure Exists

FThe honest headline: no approved cure

It must be stated plainly: no medication is approved by any major regulator to treat or cure the tinnitus percept itself [2012]. Drugs are prescribed in tinnitus care, but their role is supportive rather than curative, and the AAO-HNS guideline recommends against the routine use of drugs to treat persistent bothersome tinnitus [2014].

This honesty is therapeutic, not nihilistic. Patients who understand that no pill will switch off the sound are protected from a costly, disappointing and sometimes harmful tour of ineffective prescriptions, and are freed to engage with the interventions that do help.

TWhat drugs genuinely can do

Medication earns its place by treating the company tinnitus keeps. The most useful and evidence-based role is the management of comorbidity: antidepressants for co-existing depression or anxiety, anxiolytics or hypnotics for short-term distress or insomnia, and so on. A Cochrane review of antidepressants found the evidence for any direct effect on tinnitus to be weak, but these drugs clearly help the mood and sleep disorders that amplify tinnitus distress [2012].

The second legitimate role is treating a specific underlying disease — for example diuretics and betahistine in Ménière’s disease, or steroids in sudden sensorineural hearing loss. Here the drug targets the disorder, and any improvement in tinnitus is a downstream benefit, not a direct anti-tinnitus action. These detailed agent-by-agent roles are explored in the following modules.

CThe molecular targets being pursued

Research has nonetheless identified rational molecular targets, reflecting current models of tinnitus generation. These include glutamatergic excitotoxicity at the inner-hair-cell synapse (NMDA-receptor antagonists, trialled intratympanically), enhancement of GABA-ergic inhibition to counter central hyperactivity, modulation of potassium-channel function, and neuroprotective or antioxidant strategies to limit cochlear damage [2010].

Several candidates have reached clinical trials — intratympanic NMDA antagonists, anticonvulsants such as gabapentin, and others — but none has yet delivered a reproducible, clinically meaningful, regulator-approved benefit for chronic tinnitus. Gabapentin, for instance, failed to beat placebo in a well-conducted randomised trial of idiopathic subjective tinnitus [2007].

CWhy the trials keep failing

The repeated failure of drug trials is not merely bad luck; it reflects deep structural problems [2019]. The single largest is heterogeneity: ’tinnitus’ lumps together many different conditions with different mechanisms, so a drug effective for one subtype is diluted to non-significance across a mixed cohort. There is also no validated, objective biomarker of tinnitus, forcing reliance on subjective outcome measures.

Compounding this is the powerful placebo effect in tinnitus trials, where inert interventions can produce substantial reported improvement, narrowing the gap an active drug must beat. Add fluctuating natural history, regression to the mean, and small under-powered studies, and the result is a graveyard of promising agents. The path forward — subtyping patients, defining biomarkers, and using validated endpoints — is precisely why honest counselling today still rests on education, hearing aids and behavioural therapy rather than a prescription pad [2012].